查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401178

抗血小板药物市场 - 全球规模、占有率、趋势分析、机会、预测报告，2019-2029

Antiplatelet Drugs Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Drugs ; By Indication ; By Distribution Channel ; By Route of Administration ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年至2029年，全球抗血小板药物市场规模将以5.32%的复合年增长率成长，2029年将达到29.2亿美元。

全球抗血小板药物市场的驱动因素包括心血管疾病盛行率的上升、人口高龄化的加剧、药物开发技术的进步、预防医学意识的增强以及血栓事件一级和二级预防需求的增加，市场蓬勃发展的原因是抗血小板药物的需求迅速增加。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2022 年全球抗血小板药物市场规模为 21.4 亿美元。 2023-2029年预测期内，全球抗血小板药物市场规模预计将以5.32%的复合年增长率成长，2029年将达到29.2亿美元。全球抗血小板药物市场的成长很大程度上是由全球心血管疾病和相关问题的增加所推动的。为了满足每位患者的需求，製药公司正在专注于开发更个体化的抗血小板药物。市场上的研发活动正在迅速增加，这可能会导致新配方的开发和上市。抗血小板药物在新兴国家的使用也越来越多，刺激了市场的扩张。此外，患者依从性的提高和新的给药技术也推动了市场扩张趋势。

机会－增加医疗基础建设投资

随着全球医疗基础设施投资大幅增加，全球抗血小板药物市场已成为投资者利润丰厚的领域。随着对加强医疗设施的重视，对先进抗血小板疗法的需求不断增加。抓住机会为这一重要的医疗保健领域做出贡献，并确保获得在预防心血管事件方面发挥关键作用的创新抗血小板药物。这个市场的快速成长不仅符合全球健康优先事项，而且还为那些随着医疗保健进步而寻求永续回报的人提供了策略性投资工具。

COVID-19对全球抗血小板药物市场的影响

随着世界各地的医疗系统将重点转移到对抗病毒上，COVID-19 大大流行对全球抗血小板药物市场产生了重大影响。在大流行高峰期，选择性治疗被推迟，抗血小板药物的处方和需求减少。供应链和製造中断也导致暂时的供不应求和价格波动。然而，随着人们越来越重视远端医疗和门诊护理，以确保患者继续获得所需的药物，市场已显示出弹性。随着疫情消退，由于常规医疗服务的恢復和心血管健康意识的提高，全球抗血小板药物市场预计将復苏。

全球抗血小板药物市场－依适应症分类

依适应症，全球抗血小板药物市场分为心肌梗塞、经皮冠状动脉介入及动脉血栓症形成。心肌梗塞是全球抗血小板药物市场中最大的部分。这部分包括心臟病发作的治疗，这是一个具有全球重要性的健康问题。由于心血管疾病盛行率不断增加，心肌梗塞患者对预防血液凝固的抗血小板药物的需求仍然很高。虽然经皮冠状动脉介入和动脉血栓症形成也是重要的细分领域，但心肌梗塞对整体市场收益和成长的贡献最大，因为在这种特定疾病状态下迫切需要有效和挽救生命的治疗。

本报告的详细分析提供了有关全球抗血小板药物市场的成长潜力、未来趋势和统计数据的资讯。它还重点关注推动市场总规模预测的因素。该报告致力于提供全球抗血小板药物市场的最新技术趋势以及产业见解，帮助决策者做出策略决策。此外，我们也分析市场成长动力、挑战和竞争。

目录

第一章 研究框架

第 2 章执行摘要

第三章 全球抗血小板药物市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 心臟病和遗传性疾病的盛行率增加
      • 由于高龄化，对新型口服抗凝血药物的需求不断增加
    • 抑制因素
      • 严格的监理政策
      • 抗血栓药物高成本且副作用大
    • 机会
      • 增加研发活动
      • 加大医疗基础建设投资
    • 任务
      • 新兴经济体缺乏医疗保健基础设施
      • 一些抗血小板药物的安全性、有效性和耐受性的局限性
  • 科技进步/最新发展
  • 法律规范
  • 波特五力分析

第四章 全球抗血小板药物市场概况

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 透过药物
      • 阿斯匹灵
      • Clopidogrel
      • 奇卡古雷勒
      • 普拉格雷
      • 其他的
    • 按指示
      • 心肌梗塞
      • 经皮冠状动脉介入
      • 动脉血栓症
      • 其他的
    • 按配销通路
      • 医院药房
      • 零售药房
      • 线上药房
      • 其他的
    • 依给药途径
      • 口服
      • 注射
    • 按最终用途
      • 医院
      • 专科诊所
      • 居家护理
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第五章 北美抗血小板药物市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 透过药物
    • 按指示
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 美国
      • 加拿大

第六章 欧洲抗血小板药物市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 透过药物
    • 按指示
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他的

第七章亚太地区抗血小板药物市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 透过药物
    • 按指示
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他的

第八章拉丁美洲抗血小板药物市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 透过药物
    • 按指示
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他的

第九章中东和非洲抗血小板药物市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 透过药物
    • 按指示
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他的

第10章竞争形势

  • 主要企业及其产品列表
  • 2022年全球抗血小板药企业市场占有率分析
  • 透过管理参数进行竞争基准化分析
  • 主要策略发展（合併、收购、合作伙伴关係等）

第十一章 新型冠状病毒感染疾病（COVID-19）对全球抗血小板药物市场的影响

第十二章 公司简介（公司简介、财务矩阵、竞争形势、关键人力资源、主要竞争、联络地址、策略展望、SWOT分析）

  • Eli Lilly and Company
  • Pfizer Inc.
  • GSK Group of Companies（US）
  • Novartis AG
  • EnBiotix Inc.
  • Johnson &Johnson Private Limited
  • Merck &Co., Inc.
  • Alexion Pharmaceuticals, Inc.
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AnaSpec
  • AMP Biotech
  • Phoenix Biotechnology Inc.
  • Novabiotics
  • Ontores Biotechnologies Inc.
  • 其他主要企业

第十三章 主要战略建议

第14章调查方法

简介目录
Product Code: BWC231048

Global Antiplatelet Drugs Market Size Grows at CAGR of 5.32% During 2023-2029 to Reach USD 2.92 Billion by 2029

Global antiplatelet drugs market is flourishing due to the increasing prevalence of cardiovascular diseases, the growing aging population, advancements in drug development technologies, growing awareness about preventive healthcare, and a surge in demand for antiplatelet drugs for primary and secondary prevention of thrombotic events.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antiplatelet Drugs Market size at USD 2.14 billion in 2022. During the forecast period between 2023 and 2029, the Global Antiplatelet Drugs Market size is to grow at a CAGR of 5.32% reaching a value of USD 2.92 billion by 2029. An increase in cardiovascular illnesses and associated problems worldwide are major factors behind the growth of the global market for antiplatelet medicines. To meet the demands of each patient specifically, pharmaceutical companies are concentrating on creating more sophisticated and individualized antiplatelet medicines. The market is witnessing a rapid increase in R&D activities, which could result in the development and launch of novel drug formulations. Antiplatelet medications are also being used more frequently in emerging economies, which is fueling market expansion. Also, improvements in patient compliance and new drug delivery techniques are adding to the market's upward trend.

Opportunity - Increasing Investments in Healthcare Infrastructure

As worldwide healthcare infrastructure experiences a significant upswing in investments, the Global Antiplatelet Drugs Market emerges as a lucrative sector for prospective investors. With a rising focus on enhancing medical facilities, there is a growing demand for advanced antiplatelet therapies. Seize the opportunity to contribute to this vital healthcare segment, ensuring access to innovative antiplatelet drugs that play a crucial role in preventing cardiovascular events. This market surge not only aligns with global health priorities but also presents a strategic investment avenue for those seeking sustainable returns in the flourishing landscape of healthcare advancements.

Impact of COVID-19 on Global Antiplatelet Drugs Market

The COVID-19 pandemic significantly impacted Global Antiplatelet Drugs Market, as healthcare systems worldwide shifted focus to combat the virus. During the peak of the pandemic, elective procedures were postponed, leading to reduced prescriptions and demand for antiplatelet drugs. Also, disruptions in the supply chain and manufacturing caused temporary shortages and price fluctuations. However, the market showed resilience with the increasing emphasis on telemedicine and outpatient care, ensuring continuous patient access to essential medications. As the pandemic abates, the Global Antiplatelet Drugs Market is expected to rebound, driven by the resumption of routine medical services and growing awareness of cardiovascular health.

Global Antiplatelet Drugs Market - By Indication

By indication, Global Antiplatelet Drugs Market is divided into Myocardial infarction, Percutaneous Coronary Interventions, and Arterial Thrombosis segments. Myocardial infarction is the largest segment in the Global Antiplatelet Drugs Market. The segment encompasses the treatment of heart attacks, which is a significant health concern worldwide. The demand for antiplatelet drugs to prevent blood clotting in patients suffering from myocardial infarction remains high due to the increasing prevalence of cardiovascular diseases. While percutaneous coronary interventions and arterial thrombosis are also important segments, myocardial infarction stands out as the most substantial contributor to the overall market revenue and growth, driven by the critical need for effective and life-saving treatments in this specific medical condition.

Competitive Landscape

Global Antiplatelet Drugs Market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Antiplatelet Drugs Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antiplatelet Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antiplatelet Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Drugs Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antiplatelet Drugs Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increase in the prevalence of cardiac and hereditary diseases
      • 3.2.1.2. Growing demand for novel oral anticoagulants coupled with the aging population
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent regulatory policies
      • 3.2.2.2. High cost and side effects of antithrombotic drugs
    • 3.2.3. Opportunities
      • 3.2.3.1. Increase in the number of research and development activities
      • 3.2.3.2. Increasing investment in healthcare infrastructure
    • 3.2.4. Challenges
      • 3.2.4.1. Lack of healthcare infrastructure in developing economies
      • 3.2.4.2. Limitations in safety, efficacy, and tolerability of some antiplatelet drugs
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antiplatelet Drugs Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drugs
      • 4.2.1.1. Aspirin
      • 4.2.1.2. Clopidogrel
      • 4.2.1.3. Ticagrelor
      • 4.2.1.4. Prasugrel
      • 4.2.1.5. Others
    • 4.2.2. By Indication
      • 4.2.2.1. Myocardial Infraction
      • 4.2.2.2. Percutaneous Coronary Interventions
      • 4.2.2.3. Arterial Thrombosis
      • 4.2.2.4. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacy
      • 4.2.3.2. Retail Pharmacy
      • 4.2.3.3. Online Pharmacy
      • 4.2.3.4. Others
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
    • 4.2.5. By End Use
      • 4.2.5.1. Hospitals
      • 4.2.5.2. Specialty Clinics
      • 4.2.5.3. Homecare
      • 4.2.5.4. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Antiplatelet Drugs Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs
    • 5.2.2. By Indication
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Route of Administration
    • 5.2.5. By End Use
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By Drugs
      • 5.2.6.1.2. By Indication
      • 5.2.6.1.3. By Distribution Channel
      • 5.2.6.1.4. By Route of Administration
      • 5.2.6.1.5. By End Use
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By Drugs
      • 5.2.6.2.2. By Indication
      • 5.2.6.2.3. By Distribution Channel
      • 5.2.6.2.4. By Route of Administration
      • 5.2.6.2.5. By End Use

6. Europe Antiplatelet Drugs Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Use
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By Drugs
      • 6.2.6.1.2. By Indication
      • 6.2.6.1.3. By Distribution Channel
      • 6.2.6.1.4. By Route of Administration
      • 6.2.6.1.5. By End Use
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By Drugs
      • 6.2.6.2.2. By Indication
      • 6.2.6.2.3. By Distribution Channel
      • 6.2.6.2.4. By Route of Administration
      • 6.2.6.2.5. By End Use
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By Drugs
      • 6.2.6.3.2. By Indication
      • 6.2.6.3.3. By Distribution Channel
      • 6.2.6.3.4. By Route of Administration
      • 6.2.6.3.5. By End Use
      • 6.2.6.4. France
      • 6.2.6.4.1. By Drugs
      • 6.2.6.4.2. By Indication
      • 6.2.6.4.3. By Distribution Channel
      • 6.2.6.4.4. By Route of Administration
      • 6.2.6.4.5. By End Use
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By Drugs
      • 6.2.6.5.2. By Indication
      • 6.2.6.5.3. By Distribution Channel
      • 6.2.6.5.4. By Route of Administration
      • 6.2.6.5.5. By End Use
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By Drugs
      • 6.2.6.6.2. By Indication
      • 6.2.6.6.3. By Distribution Channel
      • 6.2.6.6.4. By Route of Administration
      • 6.2.6.6.5. By End Use
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By Drugs
      • 6.2.6.7.2. By Indication
      • 6.2.6.7.3. By Distribution Channel
      • 6.2.6.7.4. By Route of Administration
      • 6.2.6.7.5. By End Use
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By Drugs
      • 6.2.6.8.2. By Indication
      • 6.2.6.8.3. By Distribution Channel
      • 6.2.6.8.4. By Route of Administration
      • 6.2.6.8.5. By End Use
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By Drugs
      • 6.2.6.9.2. By Indication
      • 6.2.6.9.3. By Distribution Channel
      • 6.2.6.9.4. By Route of Administration
      • 6.2.6.9.5. By End Use

7. Asia Pacific Antiplatelet Drugs Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Use
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By Drugs
      • 7.2.6.1.2. By Indication
      • 7.2.6.1.3. By Distribution Channel
      • 7.2.6.1.4. By Route of Administration
      • 7.2.6.1.5. By End Use
      • 7.2.6.2. India
      • 7.2.6.2.1. By Drugs
      • 7.2.6.2.2. By Indication
      • 7.2.6.2.3. By Distribution Channel
      • 7.2.6.2.4. By Route of Administration
      • 7.2.6.2.5. By End Use
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By Drugs
      • 7.2.6.3.2. By Indication
      • 7.2.6.3.3. By Distribution Channel
      • 7.2.6.3.4. By Route of Administration
      • 7.2.6.3.5. By End Use
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By Drugs
      • 7.2.6.4.2. By Indication
      • 7.2.6.4.3. By Distribution Channel
      • 7.2.6.4.4. By Route of Administration
      • 7.2.6.4.5. By End Use
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By Drugs
      • 7.2.6.5.2. By Indication
      • 7.2.6.5.3. By Distribution Channel
      • 7.2.6.5.4. By Route of Administration
      • 7.2.6.5.5. By End Use
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By Drugs
      • 7.2.6.6.2. By Indication
      • 7.2.6.6.3. By Distribution Channel
      • 7.2.6.6.4. By Route of Administration
      • 7.2.6.6.5. By End Use
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By Drugs
      • 7.2.6.7.2. By Indication
      • 7.2.6.7.3. By Distribution Channel
      • 7.2.6.7.4. By Route of Administration
      • 7.2.6.7.5. By End Use
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By Drugs
      • 7.2.6.8.2. By Indication
      • 7.2.6.8.3. By Distribution Channel
      • 7.2.6.8.4. By Route of Administration
      • 7.2.6.8.5. By End Use
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By Drugs
      • 7.2.6.9.2. By Indication
      • 7.2.6.9.3. By Distribution Channel
      • 7.2.6.9.4. By Route of Administration
      • 7.2.6.9.5. By End Use
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By Drugs
      • 7.2.6.10.2. By Indication
      • 7.2.6.10.3. By Distribution Channel
      • 7.2.6.10.4. By Route of Administration
      • 7.2.6.10.5. By End Use

8. Latin America Antiplatelet Drugs Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Use
    • 8.2.6. By Country
      • 8.2.6.1. Brazil
      • 8.2.6.1.1. By Drugs
      • 8.2.6.1.2. By Indication
      • 8.2.6.1.3. By Distribution Channel
      • 8.2.6.1.4. By Route of Administration
      • 8.2.6.1.5. By End Use
      • 8.2.6.2. Mexico
      • 8.2.6.2.1. By Drugs
      • 8.2.6.2.2. By Indication
      • 8.2.6.2.3. By Distribution Channel
      • 8.2.6.2.4. By Route of Administration
      • 8.2.6.2.5. By End Use
      • 8.2.6.3. Argentina
      • 8.2.6.3.1. By Drugs
      • 8.2.6.3.2. By Indication
      • 8.2.6.3.3. By Distribution Channel
      • 8.2.6.3.4. By Route of Administration
      • 8.2.6.3.5. By End Use
      • 8.2.6.4. Peru
      • 8.2.6.4.1. By Drugs
      • 8.2.6.4.2. By Indication
      • 8.2.6.4.3. By Distribution Channel
      • 8.2.6.4.4. By Route of Administration
      • 8.2.6.4.5. By End Use
      • 8.2.6.5. Rest of LATAM
      • 8.2.6.5.1. By Drugs
      • 8.2.6.5.2. By Indication
      • 8.2.6.5.3. By Distribution Channel
      • 8.2.6.5.4. By Route of Administration
      • 8.2.6.5.5. By End Use

9. Middle East and Africa Antiplatelet Drugs Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Use
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By Drugs
      • 9.2.6.1.2. By Indication
      • 9.2.6.1.3. By Distribution Channel
      • 9.2.6.1.4. By Route of Administration
      • 9.2.6.1.5. By End Use
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By Drugs
      • 9.2.6.2.2. By Indication
      • 9.2.6.2.3. By Distribution Channel
      • 9.2.6.2.4. By Route of Administration
      • 9.2.6.2.5. By End Use
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By Drugs
      • 9.2.6.3.2. By Indication
      • 9.2.6.3.3. By Distribution Channel
      • 9.2.6.3.4. By Route of Administration
      • 9.2.6.3.5. By End Use
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By Drugs
      • 9.2.6.4.2. By Indication
      • 9.2.6.4.3. By Distribution Channel
      • 9.2.6.4.4. By Route of Administration
      • 9.2.6.4.5. By End Use
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By Drugs
      • 9.2.6.5.2. By Indication
      • 9.2.6.5.3. By Distribution Channel
      • 9.2.6.5.4. By Route of Administration
      • 9.2.6.5.5. By End Use
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By Drugs
      • 9.2.6.6.2. By Indication
      • 9.2.6.6.3. By Distribution Channel
      • 9.2.6.6.4. By Route of Administration
      • 9.2.6.6.5. By End Use
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By Drugs
      • 9.2.6.7.2. By Indication
      • 9.2.6.7.3. By Distribution Channel
      • 9.2.6.7.4. By Route of Administration
      • 9.2.6.7.5. By End Use
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By Drugs
      • 9.2.6.8.2. By Indication
      • 9.2.6.8.3. By Distribution Channel
      • 9.2.6.8.4. By Route of Administration
      • 9.2.6.8.5. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antiplatelet Drugs Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of COVID-19 on Global Antiplatelet Drugs Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Eli Lilly and Company
  • 12.2. Pfizer Inc.
  • 12.3. GSK Group of Companies (U.S)
  • 12.4. Novartis AG
  • 12.5. EnBiotix Inc.
  • 12.6. Johnson & Johnson Private Limited
  • 12.7. Merck & Co., Inc.
  • 12.8. Alexion Pharmaceuticals, Inc.
  • 12.9. Melinta Therapeutics, LLC
  • 12.10. Vertex Pharmaceuticals Incorporated
  • 12.11. AnaSpec
  • 12.12. AMP Biotech
  • 12.13. Phoenix Biotechnology Inc.
  • 12.14. Novabiotics
  • 12.15. Ontores Biotechnologies Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations